Alirocumab is tied to improved lipids in T2D with ASCVD

  • Ray KK & al.
  • Cardiovasc Diabetol
  • 09.11.2019

  • von Miriam Tucker
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Alirocumab reduces atherogenic cholesterol and low-density lipoprotein (LDL) particle number (LDL-PN) among people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). 
  • These patients had high non-high-density lipoprotein-cholesterol (HDL-C)/LDL-cholesterol (LDL-C) levels despite maximally tolerated statin treatment.

Why this matters

  • ASCVD is the leading cause of morbidity and mortality for individuals with diabetes.

Study design

  • Analysis of alirocumab efficacy and safety in pooled data from ODYSSEY DM-DYSLIPIDEMIA (n=142) and ODYSSEY DM-INSULIN (n=177), in people with T2D, high LDL-C/non-HDL-C, and established ASCVD despite maximum tolerated statin dose.
  • Funding: Sanofi; Regeneron Pharmaceuticals, Inc.  

Key results

  • Alirocumab was tied to significantly reduced non-HDL-C, LDL-C, apolipoprotein B (ApoB), and LDL-PN from baseline to week 24 vs controls in both studies.
  • At week 24, vs control, a significantly greater proportion achieved:
    • Non-HDL-C
    • LDL-C
    • ApoB
  • For LDL-C
  • Overall, 66.7% (alirocumab) and 67.3% (control) reported treatment-emergent adverse events.
    • These events were serious in 9.5% (drug) vs 8.8% (control) in DM-DYSLIPIDEMIA and 9.0% (drug) vs 9.4% (control) in DM-INSULIN.

Limitations

  • Studies had different designs.